Alexza completes FDA review for AZ-004 NDA Alexza Pharmaceuticals, Inc. announced today that it finished an End-of-Review ending up in the U.S. Meals and Medication Administration for the AZ-004 New Drug Application , and has received the official FDA moments from the meeting. ‘We enjoy the FDA’s review of the 1st NDA for our novel Staccato technology and we will work to address issues raised in the Complete Response Letter,’ stated Thomas B. King, Alexza President and CEO.in October 2010 ‘ As reported, the FDA stated in the CRL that their major clinical security concern was related to data from the three Phase 1 pulmonary safety research with AZ-004. Related StoriesMayo Clinic study analyzes asthma outcomes after individuals stage down daily medicinesResearchers find protein that plays crucial function in advancement of allergic airway inflammationResearchers compare effectiveness of combination therapy for black sufferers with asthmaIn the info package, Alexza also demonstrated that the pulmonary safety program in subjects with asthma and COPD had identified sufferers who may be susceptible to bronchospasm, the nature of this event, how it can be handled, and that Alexza believed the risk in these sufferers could be mitigated through labeling and a Risk Evaluation and Mitigation Strategy program.Related StoriesNew UCLA research talks about primary care medical house in reducing childrens' repeat appointments to hospitalsNew research uncovers antibiotic prescription styles across EnglandBoston Children's Hospital selects Vijay G. Sankaran to receive Rising Superstar AwardResistance to antibiotics is usually increasing, compromising their overall effectiveness in treating infections with antibiotics. The debate about the impact of animal usage of antibiotics on human health provides been raging for more than 25 years. In a scientific review released in Clinical Infectious Illnesses in October 2011, Co-writer and Levy Bonnie Marshall, of Tufts University School of Medicine also, analyzed scientific proof on the use of antibiotics in animal husbandry and aquaculture for nontherapeutic purposes and reported mind-boggling evidence that nontherapeutic use of antibiotics plays a part in antibiotic resistance, also if all the mechanisms in the genetic transmission chain are not yet fully understood.